AFFIRIS

AFFiRiS is a clinical-stage biopharmaceutical company that pursues the ultimate aim to improve the lives of patients suffering from chronic diseases by providing specific active immunotherapies (SAIT) based on its proprietary patented AFFITOME® technology. We strive to deliver much-needed therapies for patients with chronic diseases... Adherence to current therapies can be poor due to complex dosing regimens, and the treatment of many chronic diseases is still inadequate. Using our unique AFFITOME technology, we are developing Specific Active ImmunoTherapy (SAIT), which stimulates the body to find and fight proteins central to the development and progression of chronic diseases. SAIT induces a long‑lasting target-specific immune response, which may be generated by far less frequent dosing regimens (e.g., once or twice a year)... We are a clinical‑stage biotechnology company striving to deliver novel therapies to patients with neurodegenerative diseases

Also known as: Affiris AG, AFFiRiS CVD GmbH

Primary location: Vienna Austria